Advertisement

Biopharmaceutical Processes

  • Anthony J. Hickey
  • Stefano Giovagnoli
Chapter
Part of the AAPS Introductions in the Pharmaceutical Sciences book series (AAPSINSTR)

Abstract

The knowledge of drug’s biopharmaceutical profile is of paramount importance to design dosage forms able to overcome the countless drug delivery challenges. To this purpose, control upon the way the drug is released from the pharmaceutical form is fundamental along with the insightful understanding of all pathophysiological factors that strongly influence drug’s bioavailability and fate into the body. Although generally well addressed, many biopharmaceutical aspects remain challenging and require a continuous learning effort.

References

  1. 1.
    Fan J, De Lannoy IAM. Pharmacokinetics. Biochem Pharmacol. 2014;87:93–120.CrossRefPubMedGoogle Scholar
  2. 2.
    van de Waterbeemd H, Testa B. Introduction: the why and how of drug bioavailability research. In: van de Waterbeemd H, Testa B, editors. Drug bioavailability: estimation of solubility, permeability, absorption and bioavailability [Internet]. 2nd Edition. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2008. p. 1–6. Available from: http://doi.wiley.com/10.1002/9783527623860.ch1.
  3. 3.
    Sachan N, Bhattacharya A, Pushkar S, Mishra A. Biopharmaceutical classification system: a strategic tool for oral drug delivery technology. Asian J Pharm. 2009;3(2):76. [Internet]. Available from: http://www.asiapharmaceutics.info/text.asp?2009/3/2/76/55042CrossRefGoogle Scholar
  4. 4.
    Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1:337–41.CrossRefPubMedGoogle Scholar
  5. 5.
    Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2012;64:4–17.CrossRefGoogle Scholar
  6. 6.
    Vimalson DC, Parimalakrishnan S, Jeganathan NS, Anbazhagan S. Techniques to enhance solubility of hydrophobic drugs: an overview. Asian J Pharm. 2016;10(2):1–5.Google Scholar
  7. 7.
    Gomez-Orellana I. Strategies to improve oral drug bioavailability. Expert Opin Drug Deliv. 2005;2(3):419–33. [Internet]. Available from: http://www.tandfonline.com/doi/full/10.1517/17425247.2.3.419CrossRefPubMedGoogle Scholar
  8. 8.
    Taylor JB, Triggle DJ, Avdeef A, Voloboy D, Foreman A. Dissolution and solubility. Compr Med Chem II. 2007:399–423. [Internet]. Available from: http://www.sciencedirect.com/science/article/pii/B008045044X001346
  9. 9.
    Frenning G, Strømme M. Drug release modeled by dissolution, diffusion, and immobilization. Int J Pharm. 2003;250(1):137–45.CrossRefPubMedGoogle Scholar
  10. 10.
    Jain S, Patel N, Lin S. Solubility and dissolution enhancement strategies: current understanding and recent trends. Drug Dev Ind Pharm. 2015;41:875–87.CrossRefPubMedGoogle Scholar
  11. 11.
    Nelson KG, Shah AC. Convective diffusion model for a transport-controlled dissolution rate process. J Pharm Sci. 1975;64(4):610–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Censi R, Di Martino P. Polymorph impact on the bioavailability and stability of poorly soluble drugs. Molecules. 2015;20(10):18759–76.CrossRefPubMedGoogle Scholar
  13. 13.
    Desai PM, Liew CV, Heng PWS. Review of disintegrants and the disintegration phenomena. J Pharm Sci. 2016;105:2545–55.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Anthony J. Hickey
    • 1
  • Stefano Giovagnoli
    • 2
  1. 1.Discovery Science and TechnologyRTI InternationalResearch Triangle ParkUSA
  2. 2.Department of Pharmaceutical SciencesUniversity of PerugiaPerugiaItaly

Personalised recommendations